PSORIASIS

Most Recent Psoriasis Updates

1. Inflammation. 2023 Feb 7. doi: 10.1007/s10753-023-01785-7. Online ahead of

print.

Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Psoriasis Through

TNF-α/NF-κB/MMP13 Pathway.

Ren X(#)(1), Zhong W(#)(2), Li W(2), Tang M(1), Zhang K(2), Zhou F(3), Shi X(3),

Wu J(3), Yu B(2), Huang C(4), Chen X(5), Zhang W(6)(7).

Author information:

(1)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical

Research Institute, Shenzhen Peking University - the Hong Kong University of

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province,

China.

(2)Department of Dermatology, Peking University Shenzhen Hospital, No. 1120,

Lianhua Road, Shenzhen, 518036, China.

(3)Department of Neurology, Peking University Shenzhen Hospital, No. 1120,

Lianhua Road, Shenzhen, 518036, China.

(4)Department of Dermatology, Peking University Shenzhen Hospital, No. 1120,

Lianhua Road, Shenzhen, 518036, China. conghuangphd1988@163.com.

(5)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical

Research Institute, Shenzhen Peking University - the Hong Kong University of

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province,

China. littlecanva@163.com.

(6)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical

Research Institute, Shenzhen Peking University - the Hong Kong University of

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province,

China. zhangweispace@yeah.net.

(7)Greater Bay Biomedical Innocenter, Shenzhen Bay Laboratory, Shenzhen,

Guangdong Province, China. zhangweispace@yeah.net.

(#)Contributed equally

Psoriasis is a chronic, immune-mediated disease that affects 2-3% of the global

population. Recently, mesenchymal stem cells (MSCs) have been used to alleviate

psoriasis. However, the therapeutic mechanisms of MSCs remain unclear. Matrix

metalloproteinase-13 (MMP13), a member of the MMPs family, is the key enzyme in

the cleavage of type II collagen and plays a pivotal role in extracellular

matrix (ECM) remodeling. Here, it was found that Mmp13 was upregulated in the

skin lesions of an imiquimod-induced mouse model, which was downregulated after

intravenous infusion of human umbilical cord MSCs (hUC-MSCs). Knockdown of MMP13

inhibited the proliferation of keratinocytes and arrested the cell cycle in G1

stage. In addition, hUC-MSCs were co-cultured with THP-1 or PMA-stimulated THP-1

directly in vitro to simulate the fate of systematically infused hUC-MSCs. The

level of TNF-α was decreased in the supernatant of co-cultured hUC-MSCs and

THP-1 or PMA-stimulated THP-1. Moreover, it was identified that TNF-α

upregulated MMP13 through the NF-κB pathway in keratinocytes. In conclusion, we

propose that systematically infused hUC-MSCs exert a therapeutic effect on

psoriasis through the TNF-α/NF-κB/MMP13 pathway.

Media, LLC, part of Springer Nature.

DOI: 10.1007/s10753-023-01785-7

PMID: 36749439

2. Arch Dermatol Res. 2023 Feb 7. doi: 10.1007/s00403-023-02546-0. Online ahead of

print.

The patient perspective on vaccine uptake in adults with psoriasis and eczema.

Noe MH(1), Archila M(2), Barbieri JS(2), Goldman N(2)(3), Lopez CG(2),

Mostaghimi A(2), Scherer AM(4), Tan AJ(2)(5), Perez-Chada LM(2), Asgari

MM(6)(7), Gelfand JM(8)(9).

Author information:

(1)Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.

mnoe2@bwh.harvard.edu.

(2)Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.

(3)School of Medicine, New York Medical College, New York, NY, USA.

(4)Department of Internal Medicine, University of Iowa, Iowa, IA, USA.

(5)University of Massachusetts Medical School, Worcester, MA, USA.

(6)Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.

(7)Department of Population Medicine, Harvard Medical School, Boston, MA, USA.

(8)Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

(9)Center for Clinical Epidemiology and Biostatistics, University of

Pennsylvania, Philadelphia, PA, USA.

Having a chronic disease is one of the most consistent factors associated with

vaccine uptake for adults in the general population, but vaccination beliefs and

behaviors specific to those with chronic skin diseases have not been explored.

The objective of this study was to explore factors associated with vaccine

uptake and barriers to vaccination in adults with psoriasis and eczema. Virtual,

video-based semi-structured interviews were performed with adults who

self-reported a diagnosis of psoriasis or eczema. Interviews explored themes

around healthcare decision making, perceived risks/benefits to vaccination,

barriers, and vaccine knowledge. Thematic analysis was used to analyze the data.

Of 34 study participants, 25 participants (74%) were females and 9 (26%) were

males, with a mean age of 50.8 years (SD: 16.4, range: 24-71 yrs). Half of

participants (n = 17) had psoriasis, and half (n = 17) had eczema. Participants

recognized both personal and societal benefits to vaccines. Common vaccination

barriers identified were access to appointments, concerns about side effects,

and misinformation. Physicians, friends/family, and media, including internet

resources, were health information resources identified by patients. These

results summarize the unique patient perspective around vaccine uptake in adults

with eczema and psoriasis and represent an important first step in a

multi-pronged approach to improve vaccination rates in adults with chronic skin

diseases.

part of Springer Nature.

DOI: 10.1007/s00403-023-02546-0

PMID: 36749390

3. J Dtsch Dermatol Ges. 2023 Feb 7. doi: 10.1111/ddg.14934. Online ahead of print.

The impact of surgical interventions on the psychosocial well-being of patients

with hidradenitis suppurativa.

Scholl L(1), Schneider-Burrus S(2)(3), Fritz B(4), Sabat R(3)(5)(6), Bechara

FG(1).

Author information:

(1)Department of Dermatology, Venerology, and Allergology - St. Josef-Hospital,

Ruhr-University Bochum, Bochum, Germany.

(2)Centre for Dermatosurgery, Havelklinik, Berlin, Germany.

(3)Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical

Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

(4)AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.

(5)Psoriasis Research and Treatment Center, Charité - Universitätsmedizin

Berlin, Berlin, Germany.

(6)Inflammation and Regeneration of Skin, BIH Center for Regenerative Therapies,

Charité - Universitätsmedizin Berlin, Berlin, Germany.

BACKGROUND AND OBJECTIVES: Hidradenitis suppurativa is a chronic inflammatory

skin disease. Depending on disease severity, a combination of conservative and

surgical treatments is necessary. This analysis aimed to determine the impact of

surgical interventions on patient psychosocial well-being.

PATIENTS AND METHODS: This is a prospective, noninterventional, multicenter

study. The medical history, medical examination, and patient-reported outcomes,

including the Hospital Anxiety and Depression Scale, Dermatology Life Quality

Index, and the Short Form-12 Health Survey, were collected from 481 patients

with hidradenitis suppurativa.

RESULTS: Among all patients with hidradenitis suppurativa included in this

study, 74.2% reported surgery before study inclusion, of whom 92.4% could

identify surgery type and location. Although adjusted for confounding factors,

such as disease severity and activity, the aforementioned patient reported

outcomes, did not vary significantly between groups of patients with different

techniques and number of prior surgical intervention. However, patients without

any prior surgical intervention yielded significantly better scores.

CONCLUSIONS: In patients with hidradenitis suppurativa, previous surgery was

associated with worse outcomes in anxiety, depression, and quality of life,

showing the apparent need of psychological support. It remains unclear whether

the morbidity of surgical procedures or a possible higher severity score in

patients undergoing surgery is responsible.

published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische

Gesellschaft.

DOI: 10.1111/ddg.14934

PMID: 36748846

4. Diagn Progn Res. 2023 Feb 7;7(1):2. doi: 10.1186/s41512-023-00141-5.

Development and internal validation of a diagnostic prediction model for

psoriasis severity.

Liljendahl MS(1)(2), Loft N(3), Egeberg A(4), Skov L(3), Nguyen TL(5).

Author information:

(1)Department of Dermatology and Allergy, Herlev and Gentofte Hospital,

University of Copenhagen, Gentofte Hospitalsvej 15, 2900, Hellerup, Denmark.

mie.sylow.liljendahl@regionh.dk.

(2)Department of Dermatology and Venereology, Bispebjerg and Frederiksberg

Hospital, University of Copenhagen, Copenhagen, Denmark.

mie.sylow.liljendahl@regionh.dk.

(3)Department of Dermatology and Allergy, Herlev and Gentofte Hospital,

University of Copenhagen, Gentofte Hospitalsvej 15, 2900, Hellerup, Denmark.

(4)Department of Dermatology and Venereology, Bispebjerg and Frederiksberg

Hospital, University of Copenhagen, Copenhagen, Denmark.

(5)Department of Public Health, Section of Epidemiology, University of

Copenhagen, Copenhagen, Denmark.

BACKGROUND: While administrative health records such as national registries may

be useful data sources to study the epidemiology of psoriasis, they do not

generally contain information on disease severity.

OBJECTIVES: To develop a diagnostic model to distinguish psoriasis severity

based on administrative register data.

METHOD: We conducted a retrospective registry-based cohort study using the

Danish Skin Cohort linked with the Danish national registries. We developed a

diagnostic model using a gradient boosting machine learning technique to predict

moderate-to-severe psoriasis. We performed an internal validation of the model

by bootstrapping to account for any optimism.

RESULTS: Among 4016 adult psoriasis patients (55.8% women, mean age 59 years)

included in this study, 1212 (30.2%) patients were identified as having

moderate-to-severe psoriasis. The diagnostic prediction model yielded a

bootstrap-corrected discrimination performance: c-statistic equal to 0.73 [95%

CI: 0.71-0.74]. The internal validation by bootstrap correction showed no

substantial optimism in the results with a c-statistic of 0.72 [95% CI:

0.70-0.74]. A bootstrap-corrected slope of 1.10 [95% CI: 1.07-1.13] indicated a

slight under-fitting.

CONCLUSION: Based on register data, we developed a gradient boosting diagnostic

model returning acceptable prediction of patients with moderate-to-severe

psoriasis.

DOI: 10.1186/s41512-023-00141-5

PMID: 36747306

5. Int Endod J. 2023 Feb 6. doi: 10.1111/iej.13902. Online ahead of print.

Prevalence of Apical Periodontitis in Patients with Autoimmune Diseases: A Case

Control Study.

Allihaibi M(1)(2), Niazi S(1), Farzadi S(1), Austin R(3), Ideo F(4), Cotti E(4),

Mannocci F(1).

Author information:

(1)Department of Endodontics, Centre for Oral, Clinical and Translational

Sciences, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College

London, London, UK.

(2)Department of Endodontics, Faculty of Dentistry, Taif University, Taif, Saudi

Arabia.

(3)Department of Prosthodontics, Centre for Oral, Clinical and Translational

Sciences, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College

London, London, UK.

(4)Department of Conservative Dentistry and Endodontics, University of Cagliari,

Cagliari, Italy.

AIM: The purpose of this case-control study was to compare the prevalence of

Apical Periodontitis (AP) in patients affected by Autoimmune Disorders (AD)

[Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA), and Psoriasis

(Ps)] with the prevalence of AP in subjects without AD. The prevalences of AP in

patients taking biologic medications, conventional medications and no medication

were also compared.

METHODOLOGY: 89 patients (2,145 teeth) with AD were investigated and the control

group included 89 patients (2,329 teeth) with no systemic diseases. Full dental

panoramic tomograms were used to determine the periapical status of the teeth.

Additional variables investigated included patient's socio-demographic

characteristics, medications taken by AD patients, the Decayed, Missing, and

Filled Teeth (DMFT) index. The chi-square test and logistic regression analysis

were used to evaluate the correlation between AD and AP. P-values lower than

0.05 were considered to be statistically significant.

RESULTS: The prevalence of AP was 89.9% in AD patients and 74.2% in control

subjects (odds ratio [OR]=3.75, p=0.015). The DMFT score was found to be

significantly higher in the AD group (p=0.004). Patients with RA had the highest

risk of being affected by AP, whereas those with IBD had the lowest risk.

Multiple binary logistic regression analysis indicated that the teeth of AD

patients who were not taking any medication or were being treated with biologic

Disease Modifying Anti-Rheumatic Drugs (bDMARDs) had a higher risk of being

affected by AP than did the teeth of the control subjects (OR=1.42 and OR=2.03

respectively; p=0.010). The teeth of patients taking conventional DMARDs

(cDMARDs) were less affected by AP compared with those of patients taking

bDMARDs.

CONCLUSIONS: Patients with AD, whether treated or not with biologic medications,

showed a higher prevalence of AP than did those in the control group. The DMFT

index score, which was higher in AD patients compared with controls was

identified as a significant predictor of AP prevalence.

DOI: 10.1111/iej.13902

PMID: 36747086

6. Lancet. 2023 Feb 3:S0140-6736(23)00022-3. doi: 10.1016/S0140-6736(23)00022-3.

Online ahead of print.

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and

SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised,

placebo-controlled, double-blind phase 3 trials.

Kimball AB(1), Jemec GBE(2), Alavi A(3), Reguiai Z(4), Gottlieb AB(5), Bechara

FG(6), Paul C(7), Giamarellos Bourboulis EJ(8), Villani AP(9), Schwinn A(10),

Ruëff F(11), Pillay Ramaya L(12), Reich A(13), Lobo I(14), Sinclair R(15),

Passeron T(16), Martorell A(17), Mendes-Bastos P(18), Kokolakis G(19), Becherel

PA(20), Wozniak MB(21), Martinez AL(22), Wei X(23), Uhlmann L(22), Passera

A(22), Keefe D(24), Martin R(24), Field C(21), Chen L(24), Vandemeulebroecke

M(22), Ravichandran S(24), Muscianisi E(24).

Author information:

(1)Harvard Medical School and Clinical Laboratory for Epidemiology and Applied

Research in Skin, Department of Dermatology, Beth Israel Deaconess Medical

Center, Boston, MA, USA. Electronic address: clears@bidmc.harvard.edu.

(2)Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.

(3)Department of Dermatology, Mayo Clinic, Rochester, MN, USA.

(4)Dermatology Department, Polyclinique Courlancy-Bezannes, Reims, France.

(5)Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York,

NY, USA.

(6)Department of Dermatology, Venereology and Allergology, Ruhr-University

Bochum, Bochum, Germany.

(7)Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse,

France.

(8)4th Department of Internal Medicine, Medical School, National and

Kapodistrian University of Athens, Athens, Greece.

(9)Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon,

Claude Bernard Lyon I University, Lyon, France.

(10)Beldio Research, Memmingen, Germany.

(11)Department of Dermatology and Allergy, University Hospital Ludwig Maximilian

University of Munich, Munich, Germany.

(12)Department of Dermatology, Global Clinical Trials, Pretoria, South Africa.

(13)Department of Dermatology, Institute of Medical Sciences, Medical College of

Rzeszow University, Rzeszów, Poland.

(14)Centro Hospitalar do Porto, Hospital de Santo Antonio Porto, Porto,

Portugal.

(15)Sinclair Dermatology, Melbourne, VIC, Australia.

(16)Department of Dermatology Centre Hospitalier Universitaire de Nice, C3M,

INSERM U1065, Côte d'Azur University, Nice, France.

(17)Department of Dermatology, Hospital de Manises, Valencia, Spain.

(18)Dermatology Centre, Hospital Companhia União Fabril Descobertas, Lisbon,

Portugal.

(19)Psoriasis Research and Treatment Center, Department of Dermatology,

Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate

member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin,

Germany.

(20)Department of Dermatology, Venereology and Allergology, Antony Private

Hospital, Antony, France.

(21)Novartis Ireland, Dublin, Ireland.

(22)Novartis Pharma, Basel, Switzerland.

(23)Novartis Pharma Shanghai, Shanghai, China.

(24)Novartis Pharmaceuticals, East Hanover, NJ, USA.

BACKGROUND: Few therapeutic options are available for patients with

moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of

secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two

randomised trials.

METHODS: SUNSHINE and SUNRISE were identical, multicentre, randomised,

placebo-controlled, double-blind phase 3 trials done in 219 primary sites in 40

countries. Patients aged 18 years old or older with the capacity to provide

written informed consent and with moderate-to-severe hidradenitis suppurativa

(defined as a total of ≥5 inflammatory lesions affecting ≥2 distinct anatomical

areas) for at least 1 year were eligible for inclusion. Included patients also

agreed to daily use of topical over-the-counter antiseptics on the areas

affected by hidradenitis suppurativa lesions while on study treatment. Patients

were excluded if they had 20 or more fistulae at baseline, had ongoing active

conditions requiring treatment with prohibited medication (eg, systemic

biological immunomodulating treatment, live vaccines, or other investigational

treatments), or met other exclusion criteria. In both trials, patients were

randomly assigned (1:1:1) by means of interactive response technology to receive

subcutaneous secukinumab 300 mg every 2 weeks, subcutaneous secukinumab 300 mg

every 4 weeks, or subcutaneous placebo all via a 2 mL prefilled syringe in a

double-dummy method as per treatment assignment. The primary endpoint was the

proportion of patients with a hidradenitis suppurativa clinical response,

defined as a decrease in abscess and inflammatory nodule count by 50% or more

with no increase in the number of abscesses or in the number of draining

fistulae compared with baseline, at week 16, assessed in the overall population.

Hidradenitis suppurativa clinical response was calculated based on the number of

abscesses, inflammatory nodules, draining fistulae, total fistulae, and other

lesions in the hidradenitis suppurativa affected areas. Safety was assessed by

evaluating the presence of adverse events and serious adverse events according

to common terminology criteria for adverse events, which were coded using

Medical Dictionary for Regulatory Activities terminology. Both the SUNSHINE,

NCT03713619, and SUNRISE, NCT03713632, trials are registered with

ClinicalTrials.gov.

FINDINGS: Between Jan 31, 2019, and June 7, 2021, 676 patients were screened for

inclusion in the SUNSHINE trial, of whom 541 (80%; 304 [56%] women and 237 [44%]

men; mean age 36·1 years [SD 11·7]) were included in the analysis (181 [33%] in

the secukinumab every 2 weeks group, 180 [33%] in the secukinumab every 4 weeks

group, and 180 [33%] in the placebo group). Between the same recruitment dates,

687 patients were screened for inclusion in the SUNRISE trial, of whom 543 (79%;

306 [56%] women and 237 [44%] men; mean age 36·3 [11·4] years) were included in

the analysis (180 [33%] in the secukinumab every 2 weeks group, 180 [33%] in the

secukinumab every 4 weeks group, and 183 [34%] in the placebo group). In the

SUNSHINE trial, significantly more patients in the secukinumab every 2 weeks

group had a hidradenitis suppurativa clinical response (rounded average number

of patients with response in 100 imputations, 81·5 [45%] of 181 patients)

compared with the placebo group (60·7 [34%] of 180 patients; odds ratio 1·8 [95%

CI 1·1-2·7]; p=0·0070). However, there was no significant difference between the

number of patients in the secukinumab every 4 weeks group (75·2 [42%] of 180

patients) and the placebo group (1·5 [1·0-2·3]; p=0·042). Compared with the

placebo group (57·1 [31%] of 183 patients), significantly more patients in the

secukinumab every 2 weeks group (76·2 [42%] of 180 patients; 1·6 [1·1-2·6];

p=0·015) and the secukinumab every 4 weeks group (83·1 [46%] of 180 patients;

1·9 [1·2-3·0]; p=0·0022) had a hidradenitis suppurativa clinical response in the

SUNRISE trial. Patient responses were sustained up to the end of the trials at

week 52. The most common adverse event by preferred term up to week 16 was

headache in both the SUNSHINE (17 [9%] patients in the secukinumab every 2 weeks

group, 20 [11%] in the secukinumab every 4 weeks group, and 14 [8%] in the

placebo group) and SUNRISE (21 [12%] patients in the secukinumab every 2 weeks

group, 17 [9%] in the secukinumab every 4 weeks group, and 15 [8%] in the

placebo group) trials. No study-related deaths were reported up to week 16. The

safety profile of secukinumab in both trials was consistent with that previously

reported, with no new or unexpected safety findings detected.

INTERPRETATION: When given every 2 weeks, secukinumab was clinically effective

at rapidly improving signs and symptoms of hidradenitis suppurativa with a

favourable safety profile and with sustained response up to 52 weeks of

treatment.

FUNDING: Novartis Pharma.

DOI: 10.1016/S0140-6736(23)00022-3

PMID: 36746171

Conflict of interest statement: Declaration of interests ABK reports grants from

AbbVie, Anapyts Bio, Aristea, Bristol Myers Squibb, ChemoCentryx, Eli Lilly,

Incyte, Janssen, Moonlake, Novartis, Pfizer, UCB, and Sonoma Bio and fellowship

funding from AbbVie and Janssen paid to her institution; royalties from BIDMC;

consulting fees from AbbVie, Alumis, Bayer, Bristol Myers Squibb,

Boehringer-Ingelheim, Eli Lilly, FIDE, Novartis, Moonlake, Janssen, Pfizer,

Priovant, Sonoma Bio, Sanofi, Target RWE, UCB, and Ventyx; stock in Ventyx;

serving on advisory boards for Target RWE; serving as an advisory council member

to the National Institute of Health Director; and serves on the board of

directors of Almirall. GBEJ reports grants from AbbVie, Boehringer-Ingelheim,

CSL Behring, Regeneron, InflaRx, Novartis, LEO Foundation, and UCB, paid to

their institution, and honoraria for advisory board meetings from Coloplast,

Union Therapeutics, Toosonix, Boehringer-Ingelheim, Kymera, Sanofi, Viela Bio,

ChemoCentryx, LEO Pharma, Afyx, Incyte, InflaRx, Janssen Cilag, Novartis, and

UCB. AA reports consulting fees from AbbVie, Boehringer-Ingelheim, InflaRx, and

UCB, paid to their institution, and consulting fees from Novartis, AbbVie, and

Boehringer-Ingelheim. ZR reports consulting fees and honoraria from AbbVie,

Amgen, Janssen-Cilag, Novartis, UCB, Sanofi; consulting fees from Celltrion;

personal fees for attending meetings or for travel from AbbVie, Janssen-Cilag,

Novartis, UCB, and Sanofi; and payment for expert testimony from AbbVie, Amgen,

Celltrion, Janssen-Cilag, Novartis, and UCB. ABG reports research and

educational grants from AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun

Pharma, BMS, and UCB Pharma, paid to their institution; consulting fees from

Amgen, AnaptysBio, Avotres Therapeutics, Boehringer-Ingelheim, Bristol Myers

Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB

Pharma, and DiCE Therapeutics; honoraria as an advisory board member, or

non-promotional speaker from Amgen, AnaptysBio, Avotres Therapeutics,

Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen,

Novartis, Pfizer, Sanofi, Sun Pharma, and UCB Pharma; is a president of

International Dermatology Outcome Measures; and holds stock options in XBiotech,

for work on a rheumatoid arthritis project. FGB reports consulting fees from

AbbVie, Novartis, and UCB; honoraria and support for attending meetings or

travel from AbbVie, Janssen Cilag, Novartis, and UCB; and served on a Data

Safety Monitoring Board or Advisory Board for AbbVie, Boehringer-Ingelheim,

Janssen Cilag, Novartis, UCB, Incyte, and Moonlake. CP reports consulting fees

from Almirall, AbbVie, Amgen, BMS, Boehringer-Ingelheim, Celgene, GSK, Janssen,

LEO Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, and UCB and served on a

Data Safety Monitoring Board or Advisory Board for IQVIA. EJGB reports grants

from Horizon 2020 ImmunoSep and RISKinCOVID, Horizon Health EPIC-CROWN-2, Sobi,

bioMérieux, MSD, Abbott, Novartis, UCB, and AbbVie, paid to their institution,

and consulting fees from Sobi, Pfizer, Abbott, ThermoFisher, and Menarini. APV

reports consulting fees from Janssen-Cilag; payment or honoraria from AbbVie,

Almirall, BMS, Janssen-Cilag, Leo Pharma, Eli Lilly, MSD, Novartis, and UCB; and

support for attending meetings or travel from Janssen-Cilag and UCB. AS reports

consulting fees from Regeneron, Novartis, and AbbVie, paid to their institution;

payment or honoraria from AbbVie, Novartis, Regeneron, Sanofi; support for

attending meetings or travel from AbbVie, Janssen-Cilag, Novartis, and Sanofi;

and fees for participation on a Data Safety Monitoring Board or Advisory Board

from AbbVie, Novartis, and Sanofi. FR reports grants from ALK-Abelló,

Allergopharma, Blueprint Medicines, Mylan, Novartis, and ThermoFisher; served on

a Data Safety Monitoring Board or Advisory Board for ALK-Abelló,

Boehringer-Ingelheim, Blueprint Medicines, Leo Pharma, and UCB; and is an active

member of the German Association of Allergy and Clinical Immunology. AR and his

institution received grants from AbbVie, Alvotech, Amgen, AnaptysBio, Argenx,

Biothera, Bristol Myers Squibb, Celgene, Celltrion, Dermira, Galderma, Inflarx,

Janssen, Kiniksa, Kymab, Leo Pharma, Novartis, Pfizer, Trevi Therapeutics, and

UCB; payment or honoraria from Chema Rzeszow, Eli Lilly, Leo Pharma, Novartis,

Sandoz, and Takeda; and served on a Data Safety Monitoring Board or Advisory

Board for AbbVie, Galderma, Sandoz, and Sanofi Aventis. IL reports payment or

honoraria from Novartis and support for attending meetings or travel from

Sanofi. TP reporfts grants from Almirall, Incyte, and Pfizer, paid to their

institution, and consulting fees from AbbVie, Almirall, Bristol Myers Squibb,

Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, and UCB. AM reports

consulting fees from AbbVie, Boehringer-Ingelheim, Jansen, Eli Lilly, Novartis,

Novo Nordisk, Sandoz, and UCB; payment for expert testimony or honoraria from

AbbVie, Boehringer-Ingelheim, Jansen, Eli Lilly, Novartis, Novo Nordisk, Sandoz,

and UCB; and support for attending meetings or travel from AbbVie, Novartis,

Jansen, and UCB. PM-B reports consulting fees from AbbVie, Almirall, Eli Lilly,

Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi; payment or honoraria from

AbbVie, Almirall, Janssen, LEO Pharma, Eli Lilly, Novartis, Organon, Pfizer,

Sanofi, and Viatris; support for attending meetings or travel from AbbVie,

Almirall, Janssen, LEO Pharma, Eli Lilly, Novartis, and Sanofi; and served on a

Data Safety Monitoring Board or Advisory Board for AbbVie, Janssen, LEO Pharma,

Eli Lilly, Novartis, Pfizer, and Sanofi. GK reports consulting fees from Bayer;

payment or honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen,

Basilea Pharmaceutica, Biogen IDEC, Boehringer-Ingelheim, Bristol Myers Squibb,

Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis,

Parexel, Pfizer, and UCB; support for attending meetings or travel from AbbVie,

Abbott, Amgen, Basilea Pharmaceutica, Celgene, Janssen-Cilag, LEO Pharma, MSD,

Novartis, Pfizer, Sanofi, and UCB; and served on a Data Safety Monitoring Board

or Advisory Board for AbbVie, Abbott, Amgen, Basilea, Bayer,

Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, LEO Pharma,

Eli Lilly, Novartis, and UCB. P-AB reports consulting fees from Novartis,

AbbVie, Pfizer, and UCB pharma; payment or honoraria from Novartis and AbbVie;

support for attending meetings or travel from Novartis; and served on a Data

Safety Monitoring Board or Advisory Board for Novartis. MBW, ALM, XW, LU, AP,

DK, RM, CF, LC, MV, SR, and EM are employees of Novartis and hold company stock.

RS is Director and Founder of Samson Medical, has participated in pharmaceutical

advisory boards for Eli Lilly and Company, Pfizer, and Leo Pharmaceutical, has

participated in speaker bureaus for AbbVie, Novartis, and Pfizer, and has acted

as a principal investigator in clinical trials for AbbVie, Aerotech, Akesobio,

Amgen, Arcutis, Arena, Ascend AstraZeneca, Bayer, Biotherapeutics

Boehringer-Ingelheim, Bristol-Myer Squibb, Celgene, Coherus BioSciences,

Connect, Demira, Eli Lilly, Galderma, GlaxoSmithKline, F Hoffman–La Roche,

Janssen, MedImmune, Merck, Merck Sharpe & Dohme, Novartis, Oncobiologics,

Pfizer, Principia, Regeneron, Roche, Reistone Biopharma, Samson Clinical,

Sanofi-Genzyme, Sun Pharma UCB, Valeant, and Zai Labs. RS is President of the

Australasian Hair and Wool Research Society, and Vice President of the

International Society of Dermatology and The International Academy of

Dermatology. LPR declares no competing interests.

7. Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093/bjd/ljac132. Online ahead of

print.

Factors associated with depression, anxiety and severe mental illness among

adults with atopic eczema or psoriasis: a systematic review and meta-analysis.

Adesanya EI(1), Matthewman J(1), Schonmann Y(2)(3), Hayes JF(4), Henderson A(1),

Mathur R(1), Mulick AR(1), Smith CH(5), Langan SM(1)(6), Mansfield KE(1).

Author information:

(1)Department of Non-Communicable Disease Epidemiology, London School of Hygiene

& Tropical Medicine, London, UK.

(2)Siaal Research Center for Family Medicine and Primary Care, Faculty of Health

Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

(3)Department of Quality Measurements and Research, Clalit Health Services, Tel

Aviv, Israel.

(4)Division of Psychiatry, University College London, London, UK.

(5)St John's Institute of Dermatology, Guys and St Thomas' Foundation Trust and

King's College London, London, UK.

(6)Health Data Research UK, London, UK.

BACKGROUND: Evidence suggests an association between atopic eczema (AE) or

psoriasis and mental illness; however, the factors associated with mental

illness are unclear.

OBJECTIVES: To synthesize and evaluate all available evidence on factors

associated with depression, anxiety and severe mental illness (SMI) among adults

with AE or psoriasis.

METHODS: We searched electronic databases, grey literature databases and

clinical trial registries from inception to February 2022 for studies of adults

with AE or psoriasis. Eligible studies included randomized controlled trials

(RCTs), cohort, cross-sectional or case-control studies where effect estimates

of factors associated with depression, anxiety or SMI were reported. We did not

apply language or geographical restrictions. We assessed risk of bias using the

Quality in Prognosis Studies tool. We synthesized results narratively, and if at

least two studies were sufficiently homogeneous, we pooled effect estimates in a

random effects meta-analysis.

RESULTS: We included 21 studies (11 observational, 10 RCTs). No observational

studies in AE fulfilled our eligibility criteria. Observational studies in

people with psoriasis mostly investigated factors associated with depression or

anxiety - one cross-sectional study investigated factors associated with

schizophrenia. Pooled effect estimates suggest that female sex and psoriatic

arthritis were associated with depression [female sex: odds ratio (OR) 1.62, 95%

confidence interval (CI) 1.09-2.40, 95% prediction intervals (PIs) 0.62-4.23, I2

= 24.90%, τ2 = 0.05; psoriatic arthritis: OR 2.26, 95% CI 1.56-3.25, 95% PI

0.21-24.23, I2 = 0.00%, τ2 = 0.00] and anxiety (female sex: OR 2.59, 95% CI

1.32-5.07, 95% PI 0.00-3956.27, I2 = 61.90%, τ2 = 0.22; psoriatic arthritis: OR

1.98, 95% CI 1.33-2.94, I2 = 0.00%, τ2 = 0.00). Moderate/severe psoriasis was

associated with anxiety (OR 1.14, 95% CI 1.05-1.25, I2 0.00%, τ2 = 0.00), but

not depression. Evidence from RCTs suggested that adults with AE or psoriasis

given placebo had higher depression and anxiety scores compared with comparators

given targeted treatment (e.g. biologic agents).

CONCLUSIONS: Our review highlights limited existing research on factors

associated with depression, anxiety and SMI in adults with AE or psoriasis.

Observational evidence on factors associated with depression or anxiety in

people with psoriasis was conflicting or from single studies, but some

identified factors were consistent with those in the general population.

Evidence on factors associated with SMIs in people with AE or psoriasis was

particularly limited. Evidence from RCTs suggested that AE and psoriasis treated

with placebo was associated with higher depression and anxiety scores compared

with skin disease treated with targeted therapy; however, follow-up was limited.

Therefore, long-term effects on mental health are unclear.

Association of Dermatologists. This is an Open Access article distributed under

the terms of the Creative Commons Attribution License

(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted

reuse, distribution, and reproduction in any medium, provided the original work

is properly cited.

DOI: 10.1093/bjd/ljac132

PMID: 36745557

Conflict of interest statement: Conflicts of interest J.F.H. has received

consultancy fees from Wellcome Trust and juli Health. R.M. has received

consultancy fees from AMGEN.

8. Am J Physiol Cell Physiol. 2023 Feb 6. doi: 10.1152/ajpcell.00269.2022. Online

ahead of print.

The role of vasoactive peptides in skin homeostasis - focus on adiponectin and

the kallikrein-kinin system.

Souza-Silva IM(1), Steckelings UM(1), Assersen KB(1)(2).

Author information:

(1)Dept. of Cardiovascular and Renal Research, Institute for Molecular Medicine,

University of Southern Denmark, Odense, Denmark.

(2)Dept. of Dermatology, Odense University Hospital, Odense, Denmark.

Vasoactive peptides often serve a multitude of functions aside from their direct

effects on vasodynamics. This article will review the existing literature on two

vasoactive peptides and their involvement in skin homeostasis: adiponectin and -

as main representative of the kallikrein-kinin-system - bradykinin. Adiponectin

is the most abundantly expressed adipokine in the human organism, where it is

mainly localized in fat depots including subcutaneous adipose tissue, from where

adiponectin can exert paracrine effects. The involvement of adiponectin in skin

homeostasis is supported by a number of studies reporting effects of adiponectin

in isolated human keratinocytes, sebocytes, fibroblasts, melanocytes and immune

cells. Regarding skin pathology, the potential involvement of adiponectin in

psoriasis, atopic dermatitis, scleroderma, keloid and melanogenesis is discussed

in this article. The kallikrein-kinin-system is composed of a variety of enzymes

and peptides, most of which have been identified to be expressed in skin. This

also includes expression of bradykinin receptors on most skin cells. Bradykinin

is one of very few hormones that is targeted by a treatment in routine clinical

use in dermatology - in this case for the treatment of hereditary angioedema.

Potential involvement of bradykinin in wound healing, psoriasis and melanoma is

further discussed in this article. This review concludes with a call for

additional preclinical and clinical studies to further explore the therapeutic

potential of adiponectin supplementation (for psoriasis, atopic dermatitis,

wound healing, scleroderma and keloid) or pharmacological interference with the

kallikrein-kinin-system (for wound healing, psoriasis and melanoma).

DOI: 10.1152/ajpcell.00269.2022

PMID: 36745527

9. Australas J Dermatol. 2023 Feb 6. doi: 10.1111/ajd.13998. Online ahead of print.

Three cases of oral mucosal tuberculosis in patients on tumour-necrosis-factor-α

blockers.

Nico MMS(1), Fanciozi AB(1), da Costa ÁF(2), Lourenço SV(3).

Author information:

(1)Department of Dermatology, Medical School, University of São Paulo, São

Paulo, Brazil.

(2)Department of Infectious Diseases, Medical School, University of São Paulo,

São Paulo, Brazil.

(3)Department of Pathology, Dental School, University of São Paulo, São Paulo,

Brazil.

We present three cases of oral mucosal lesions caused by Mycobacterium

tuberculosis in patients treated with anti-tumour necrosis factor-α for

psoriasis or rheumatoid arthritis. Diagnosis of oral mucosal tuberculosis was

not easily established in any of the cases. A comparison between these cases and

other previously described forms of oral mucosal tuberculosis is presented.

DOI: 10.1111/ajd.13998

PMID: 36745517

10. J Drugs Dermatol. 2023 Feb 1;22(2):SF344607s3-SF344607s14.

Supplement Individual Article: The Importance of a Healthy Skin Barrier From the

Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A

Review and Consensus.

Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R, Woolery-Lloyd

INTRODUCTION: Inflammatory skin disorders compromise skin barrier health. Early

and daily skincare use aims to maintain a life-long healthy skin barrier.

Racial/ethnic and age variations in skin barrier properties, cultural

differences, and clinical presentation of the inflammatory skin disorder

influence the choice of treatment and skin care. Ceramide-containing skin care

may play a role in restoring and maintaining a healthy skin barrier.

METHODS: A panel of 6 dermatologists met to develop consensus statements based

on their 8 previous publications on promoting skin barrier health throughout

life using ceramide-containing skin care. The publications covered skin barrier

integrity in the newborn and infant, and the role of the skin barrier in

mitigating atopic dermatitis (AD); racial/ethnic variations in the skin barrier

and implications for skin care; the role of the skin barrier in inflammatory

skin conditions including acne, AD and psoriasis in skin of color (SOC)

populations; skin barrier integrity in patients with rosacea; and xerosis in

patients with diabetes mellitus. The panel synthesized the 8 publications,

selected information from a literature review, and their expert opinions and

experiences to create the statements. The consensus was reached through a

modified Delphi method where the panel met face-to-face and followed up

virtually.

RESULTS: The panel adopted 6 consensus statements highlighting the importance of

skin care in restoring/maintaining a healthy skin barrier in the populations

mentioned above. Skin care suited to this role is gentle, has near-physiologic

pH, is pleasant to use, and contains ceramides. This type of skin care can

promote a healthy skin barrier and attenuate or delay inflammatory skin

conditions.

CONCLUSIONS: Adjunctive daily skin care throughout life promotes a healthy skin

barrier and is beneficial in managing various inflammatory skin disorders in all

populations. However, when choosing optimal treatment and skin care, physicians

should consider variations in age, skin properties, presentation of the

condition, and cultural differences. J Drugs Dermatol. 2023;22:2(Suppl 1):s3-14.

PMID: 36745380